Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 11/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235114 | 1.00 | CTSS (0.51) | CTSSCTSKBACE1ATMGLS | |
| SCHEMBL12391806 | 0.90 | CTSS (0.46) | CTSSCTSKBACE1ATMGLS | |
| SCHEMBL1043271 | 0.90 | CTSS (0.46) | CTSSCTSKBACE1ATMGLS | |
| SCHEMBL13941145 | 0.90 | GLS (0.45) | CTSSCTSKBACE1ATMGLS | |
| SCHEMBL13494340 | 0.89 | AAK1 (0.49) | CTSSCTSKBACE1ATMGLS | |
| SCHEMBL3232601 | 0.89 | AAK1 (0.49) | CTSSCTSKBACE1ATMGLS | |
| SCHEMBL4750042 | 0.86 | CTSS (0.61) | CTSSCTSKBACE1 | |
| SCHEMBL8345117 | 0.81 | CTSS (0.51) | CTSSCTSKATMGLSMEN1 | |
| SCHEMBL8347951 | 0.81 | CTSS (0.51) | CTSSCTSKATMGLSMEN1 | |
| SCHEMBL8344155 | 0.81 | CTSS (0.51) | CTSSCTSKATMGLSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7662581-B1 | Eg5 co-crystals | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2006060737-A2 | MITOTIC KINESIN INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093767-A1 | Mitotic Kinase Inhibitors | BUB1B, BUB1, PLK1 | CTSS 1395/4885CTSK 627/4885BACE1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.